Do new protease inhibitors offer improved management options? Issues of PI tolerability and safetySAX, Paul E.Journal of acquired immune deficiency syndromes (1999). 2004, Vol 35, pp 22-34, issn 1525-4135, 13 p., SUP1Conference Paper

Tolerability and safety of HIV protease inhibitors in adultsSAX, Paul E; KUMAR, Princy.Journal of acquired immune deficiency syndromes (1999). 2004, Vol 37, Num 1, pp 1111-1124, issn 1525-4135, 14 p.Article

Potential Savings by Reduced CD4 Monitoring in Stable Patients With HIV Receiving Antiretroviral TherapyHYLE, Emily P; SAX, Paul E; WALENSKY, Rochelle P et al.JAMA internal medicine (Print). 2013, Vol 173, Num 18, pp 1746-1748, issn 2168-6106, 3 p.Article

Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphomaLVERS, Louise C; KIM, Arthur Y; SAX, Paul E et al.Clinical infectious diseases. 2004, Vol 38, Num 11, pp 1629-1632, issn 1058-4838, 4 p.Article

Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV diseaseSCHACKMAN, Bruce R; HAAS, David W; BECKER, Jessica E et al.Antiviral therapy (London). 2013, Vol 18, Num 3, pp 399-408, issn 1359-6535, 10 p.Article

Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptomsWOOD, Brian R; KOMAROW, Lauren; ZOLOPA, Andrew R et al.AIDS (London). 2013, Vol 27, Num 6, pp 967-972, issn 0269-9370, 6 p.Article

Blood (1→3)-β-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii PneumoniaSAX, Paul E; KOMAROW, Lauren; FINKELMAN, Malcolm A et al.Clinical infectious diseases. 2011, Vol 53, Num 2, pp 197-202, issn 1058-4838, 6 p.Article

Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in Elderly patients with rheumatoid arthritisSCHNEEWEISS, Sebastian; SETOGUCHI, Soko; WEINBLATT, Michael E et al.Arthritis and rheumatism. 2007, Vol 56, Num 6, pp 1754-1764, issn 0004-3591, 11 p.Article

Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individualsGANDHI, Rajesh T; WURCEL, Alysse; SAX, Paul E et al.Clinical infectious diseases. 2003, Vol 36, Num 12, pp 1602-1605, issn 1058-4838, 4 p.Article

Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infectionVIDRIH, John A; WALENSKY, Rochelle P; SAX, Paul E et al.The American journal of medicine. 2001, Vol 111, Num 3, pp 192-194, issn 0002-9343Article

Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed SuicideMOLLAN, Katie R; SMURZYNSKI, Marlene; TIERNEY, Camlin et al.Annals of internal medicine. 2014, Vol 161, Num 1, pp 1-10, issn 0003-4819, 10 p.Article

Weight and lean body mass change with antiretroviral initiation and impact on bone mineral densityERLANDSON, Kristine M; KITCH, Douglas; TIERNEY, Camlin et al.AIDS (London). 2013, Vol 27, Num 13, pp 2069-2079, issn 0269-9370, 11 p.Article

Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1: A Randomized TrialDAAR, Eric S; TIERNEY, Camlin; FARAJALLAH, Awny et al.Annals of internal medicine. 2011, Vol 154, Num 7, pp 445-456, issn 0003-4819, 12 p.Article

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202MCCOMSEY, Grace A; KITCH, Douglas; DAAR, Eric S et al.The Journal of infectious diseases. 2011, Vol 203, Num 12, pp 1791-1801, issn 0022-1899, 11 p.Article

Routine human immunodeficiency virus testing : An economic evaluation of current guidelinesWALENSKY, Rochelle P; WEINSTEIN, Milton C; KIMMEL, April D et al.The American journal of medicine. 2005, Vol 118, Num 3, pp 292-300, issn 0002-9343, 9 p.Article

Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adultsSCHACKMAN, Bruce R; FREEDBERG, Kenneth A; WEINSTEIN, Milton C et al.Archives of internal medicine (1960). 2002, Vol 162, Num 21, pp 2478-2486, issn 0003-9926, 9 p.Article

Metabolic effects of rosiglitazone in HIV lipodystrophy: A randomized, controlled trialHADIGAN, Colleen; YAWETZ, Sigal; THOMAS, Abraham et al.Annals of internal medicine. 2004, Vol 140, Num 10, pp 786-794, issn 0003-4819, 9 p.Article

Impact of randomized antiretroviral therapy initiation on glucose metabolismERLANDSON, Kristine Mace; KITCH, Douglas; TIERNEY, Camlin et al.AIDS (London). 2014, Vol 28, Num 10, pp 1451-1461, issn 0269-9370, 11 p.Article

Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare SystemTRIANT, Virginia A; REGAN, Susan; LEE, Hang et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 55, Num 5, pp 615-619, issn 1525-4135, 5 p.Article

HIV Preexposure Prophylaxis in the United States : Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost-EffectivenessPALTIEL, A. David; FREEDBERG, Kenneth A; SCOTT, Callie A et al.Clinical infectious diseases. 2009, Vol 48, Num 6, pp 806-815, issn 1058-4838, 10 p.Article

The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIVSCHACKMAN, Bruce R; SCOTT, Callie A; WALENSKY, Rochelle P et al.AIDS (London). 2008, Vol 22, Num 15, pp 2025-2033, issn 0269-9370, 9 p.Article

Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV diseaseSAX, Paul E; LOSINA, Elena; WEINSTEIN, Milton C et al.Journal of acquired immune deficiency syndromes (1999). 2005, Vol 39, Num 1, pp 69-77, issn 1525-4135, 9 p.Article

Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infectionTREMBLAY, Cecile L; HICKS, Jennifer L; D'AQUILA, Richard T et al.AIDS (London). 2003, Vol 17, Num 7, pp 1086-1089, issn 0269-9370, 4 p.Article

Antiretroviral Therapy and Efficacy After Virologic Failure on First-line Boosted Protease Inhibitor RegimensYU ZHENG; HUGHES, Michael D; HAUBRICH, Richard et al.Clinical infectious diseases. 2014, Vol 59, Num 6, pp 888-896, issn 1058-4838, 9 p.Article

Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-Boosted Atazanavir in AIDS Clinical Trials Group Study A5202RIBAUDO, Heather J; DAAR, Eric S; TIERNEY, Camlin et al.The Journal of infectious diseases. 2013, Vol 207, Num 3, pp 420-425, issn 0022-1899, 6 p.Article